| 6.46 0.43 (7.13%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.46 | 1-year : | 64.2 |
| Resists | First : | 35.5 | Second : | 54.97 |
| Pivot price | 6.03  |
|||
| Supports | First : | 4.01 | Second : | 3.33 |
| MAs | MA(5) : | 6.11 |
MA(20) : | 12.4  |
| MA(100) : | 35.87 |
MA(250) : | 36.18 |
|
| MACD | MACD : | -8.4 |
Signal : | -9.1 |
| %K %D | K(14,3) : | 71.5 |
D(3) : | 47.4 |
| RSI | RSI(14): 25.3 |
|||
| 52-week | High : | 54.97 | Low : | 4.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SION ] has closed below upper band by 20.0%. Bollinger Bands are 92.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.48 - 6.51 | 6.51 - 6.54 |
| Low: | 5.86 - 5.89 | 5.89 - 5.92 |
| Close: | 6.4 - 6.46 | 6.46 - 6.51 |
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Tue, 01 Sep 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sionna Therap - The National Law Review
Mon, 31 Aug 2026
SION INVESTIGATION: Investigation Launched into Sionna - globenewswire.com
Thu, 27 Aug 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION - PR Newswire
Wed, 26 Aug 2026
Securities Fraud Investigation Into Sionna Therapeutics, - globenewswire.com
Wed, 12 Aug 2026
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 107.1 (%) |
| Shares Short | 4,200 (K) |
| Shares Short P.Month | 5,520 (K) |
| EPS | -2.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.6 % |
| Return on Equity (ttm) | -32.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -76 (M) |
| Levered Free Cash Flow | -45 (M) |
| PE Ratio | -3.01 |
| PEG Ratio | 0 |
| Price to Book value | 1.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|